Our PPI network analysis identified key interactions between HLA-DRB5 and CD244, as well as HSD17B13 and CD244, as potential therapeutic targets in LUAD, with these genes showing downregulation in tumor tissues. This evidence concerns the gene HLA-DRB5 and neoplasm.